Generic Name and Formulations:
Albiglutide [recombinant fusion protein] 30mg, 50mg; per pen; lyophilized pwd for SC inj after reconstitution; preservative-free.
Indications for TANZEUM:
Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
Limitations Of use:
Not recommended as first-line treatment for patients inadequately controlled on diet and exercise. Not studied in combination with prandial insulin or with history of pancreatitis. Not for treating type 1 diabetes or diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients with pre-existing severe GI disease.
Give by SC inj in the abdomen, thigh, or upper arm on the same day each week without regard to meals. Rotate inj sites (esp. when concomitant insulin). Initiate at 30mg once weekly; may increase to 50mg once weekly if inadequate response. Renal impairment and/or in those with severe GI symptoms: caution with initiating or escalating doses.
<18yrs: not established.
History (personal or family) of medullary thyroid carcinoma (MTC). Multiple endocrine neoplasia syndrome type 2 (MEN 2).
Risk of thyroid C-cell tumors, including MTC; inform patients of risks and symptoms. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis; consider other antidiabetic therapies. Renal impairment and/or in those with severe GI symptoms: risk of dehydration; avoid fluid depletion. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing their doses. May affect absorption of other oral drugs (delayed gastric emptying).
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Upper respiratory tract infection, diarrhea, nausea, inj site reaction; acute pancreatitis, hypersensitivity reactions (discontinue if occurs), acute kidney injury.
Single-dose pen—4 (w. needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy